StockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel

After seeing its lead candidate rejected by the FDA last year, Capricor Therapeutics is hoping for a better outcome for its resubmitted BLA for its lead pipeline candidate Deramiocel.

The post StockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel appeared first on GEN - Genetic Engineering and Biotechnology News.